Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 1,301 Cr.
- Current Price ₹ 2,208
- High / Low ₹ 2,835 / 1,591
- Stock P/E 44.8
- Book Value ₹ 434
- Dividend Yield 0.07 %
- ROCE 23.2 %
- ROE 17.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 130 to 63.6 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 212 | 620 | |
| 185 | 575 | |
| Operating Profit | 28 | 46 |
| OPM % | 13% | 7% |
| 5 | 5 | |
| Interest | 0 | 1 |
| Depreciation | 1 | 2 |
| Profit before tax | 32 | 47 |
| Tax % | 18% | 19% |
| 26 | 38 | |
| EPS in Rs | 36.51 | 49.34 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 192% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 1 | 6 |
| Reserves | 85 | 250 |
| 12 | 23 | |
| 159 | 154 | |
| Total Liabilities | 257 | 433 |
| 12 | 16 | |
| CWIP | 0 | 0 |
| Investments | 23 | 186 |
| 223 | 231 | |
| Total Assets | 257 | 433 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 7 | |
| -9 | -11 | |
| 24 | 6 | |
| Net Cash Flow | 19 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 197 | 64 |
| Inventory Days | 95 | 35 |
| Days Payable | 208 | 49 |
| Cash Conversion Cycle | 84 | 50 |
| Working Capital Days | 68 | 65 |
| ROCE % | 23% |
Documents
Announcements
-
Press Release
17 May 2025 - Remus reports FY25 revenue INR 620 Cr, PAT INR 29 Cr; expands into new global markets.
-
General Updates
17 May 2025 - Designation of KMPs authorized for materiality and disclosure under SEBI LODR regulations.
-
Change in Management
17 May 2025 - Two directors resign as Whole Time Directors, continue as Non-Executive Non-Independent Directors from May 18, 2025.
-
General Updates
17 May 2025 - Appointment of Sharp & Tannan Associates as internal auditor for FY 2025-26.
-
General Updates
17 May 2025 - Board approved 1:1 bonus shares, doubling equity capital to Rs.11.78 crore, subject to shareholder approval.
Annual reports
Concalls
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing